Innovations in Epilepsy

Epilepsy continues to remain one of the most common chronic neurological disorders, associated with significant morbidity, affecting more than 50 million people globally.[1] The understanding of epileptogenesis has taken large strides, but still epilepsy continues to evoke challenges and fascination in equal measure. This contributes to continuously drive innovations, which have spanned pharmacological therapies, surgical and neurostimulation techniques, as well as technological developments aimed at seizure prediction and monitoring.

In the pharmacological front, newer antiepileptic drugs have expanded treatment options with improved efficacy and tolerability. Cenobamate, approved in 2019, emerged as an effective agent acting through dual mechanisms—modulating sodium channels and GABA-A receptors[2] for refractory focal seizures. Azetukalner (XEN1101), a next-generation Kv7 potassium channel opener, currently undergoing phase 3 trials has shown promise for both focal and generalized seizures, with once-daily dosing and no need for titration.[3] Repurposed agents like Fenfluramine, a drug with dual-action sigma-1 receptor and serotonergic activity,[4] were approved for Dravet syndrome in 2020.[5] Ganaxolone is also another new development, approved in 2022, which marks the first neuroactive steroid used in epilepsy management with its mechanism—enhancing tonic and phasic inhibition via GABA-A modulation[6] [7]—offering a new therapeutic avenue for syndromic epilepsies in infants and children.

Surgical and diagnostic innovations have further transformed the landscape of care. Techniques like laser interstitial thermal therapy, a minimally invasive alternative to open respective surgery, provide effective ablation of seizure foci with shorter recovery times. Magnetic resonance imaging–guided thermal ablation has proven effective in patients with mesial temporal lobe epilepsy, hypothalamic hamartomas, and focal cortical dysplasia.[8] Neurostimulation therapies have become vital tools, especially for patients not amenable to surgery. Vagus nerve stimulation, deep brain stimulation of the anterior thalamic nucleus, and responsive neurostimulation[9] [10] [11]—which delivers targeted electrical pulses upon detecting abnormal brain activity—have shown meaningful reductions in seizure frequency and are being used more regularly. Noninvasive neuromodulation techniques like transcranial magnetic stimulation are also being explored, though evidence for their efficacy remains variable.[12] Focused ultrasound, a noninvasive technique capable of lesioning epileptogenic zones or opening the blood–brain barrier for drug delivery, remains in its early stages.[13]

In cases where surgical intervention in epilepsy may be limited by factors such as bilateral seizure foci, involvement of eloquent brain regions, or multifocal epileptic networks, invasive techniques like stereo-electroencephalography (SEEG) and subdural electrodes have become key tools. SEEG, in particular, allows for high-resolution, three-dimensional mapping of epileptic activity through depth electrode implantation, offering critical localization in cases where noninvasive methods fall short. Advances in the conducting mediums including the utilization of polymer poly(3,4-ethylenedioxythiophene):poly(styrenesulfonic acid) (PEDOT:PSS) show promise for electrode modification due to their high conductivity, mechanical flexibility, and biocompatibility, making them particularly suitable for integration into neural devices for brain science research.[14]

Technological advances have enabled real-time seizure detection and prediction. Wearable devices like smart watches, accelerometers, and subcutaneous electroencephalogram (EEG) monitors can alert caregivers to convulsive seizures, improving safety during high-risk periods such as sleep.[15] Machine learning algorithms are now capable of predicting seizures with >85% sensitivity using preictal EEG and multimodal data.[16] [17] Experimental systems such as NeuroVista[18] aim to predict seizures by analyzing continuous EEG patterns, potentially allowing for preventive intervention—all driven by artificial intelligence (AI)-based seizure prediction. Apps are transforming patient engagement, improving treatment adherence, and enhancing data collection for clinical trials.

Innovation in epilepsy should not only occur isolated to treating and preventing seizures, rather it has to be comprehensive involving psychiatric, cognitive, and systemic comorbidities associated with epilepsy. In that regard, there is more awareness in recognizing depression and anxiety as a risk factor and a consequence of epilepsy. There has also been global radicalization, with the World Health Organization's Intersectoral Global Action Plan (2022–2031) for epilepsy and other neurological disorders emphasizing the integration of epilepsy services into primary care, training nonspecialists in diagnosis and treatment, access to essential medicines and diagnostic tools, and community-based rehabilitation and social support. The convergence of precision medicine, digital therapeutics, and patient-centered care marks the next frontier. Key trends to watch include: gene therapy and antisense oligonucleotides for monogenic epilepsies (e.g., SCN1A, STXBP1); microbiome-targeted therapies and dietary modulation beyond ketogenic diets; immune-modulating therapies for autoimmune epilepsies, supported by novel biomarkers (e.g., LGI1, CASPR2 antibodies); personalized polytherapy algorithms using AI-driven decision models.

The landscape of epilepsy care is being innovated, from molecular biology to wearable devices and neurosurgical precision, with research findings being converted effectively to clinical tools. Yet, it is imperative that these advances are equitably distributed across geographies and socioeconomic strata. The future is promising and demands persistent investment, interdisciplinary collaboration, and unwavering patient focus.

 

MissingLinkText

Conflict of Interests

None declared.

Availability of Data and Materials

The datasets used and/or analyzed are available from the corresponding author on reasonable request.

• References

• 1 Liu J, Zhang P, Zou Q. et al. Status of epilepsy in the tropics: an overlooked perspective. Epilepsia Open 2023; 8 (01) 32-45
• 2 Krauss GL, Klein P, Brandt C. et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol 2020; 19 (01) 38-48
• 3 French JA, Porter RJ, Perucca E. et al; X-TOLE Study Group. Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy. Epilepsia Open 2025; 10 (02) 539-548
• 4 Sourbron J, Lagae L. Fenfluramine: a plethora of mechanisms?. Front Pharmacol 2023; 14: 1192022
• 5 Simon K, Sheckley H, Anderson CL, Liu Z, Carney PR. A review of fenfluramine for the treatment of Dravet syndrome patients. Curr Res Pharmacol Drug Discov 2021; 3: 100078
• 6 Meng J, Yan Z, Tao X. et al. The efficacy and safety of ganaxolone for the treatment of refractory epilepsy: a meta-analysis from randomized controlled trials. Epilepsia Open 2023; 8 (01) 90-99
• 7 Lamb YN. Ganaxolone: first approval. Drugs 2022; 82 (08) 933-940
• 8 Prince E, Hakimian S, Ko AL, Ojemann JG, Kim MS, Miller JW. Laser interstitial thermal therapy for epilepsy. Curr Neurol Neurosci Rep 2017; 17 (09) 63
• 9 Lundstrom BN, Osman GM, Starnes K, Gregg NM, Simpson HD. Emerging approaches in neurostimulation for epilepsy. Curr Opin Neurol 2023; 36 (02) 69-76
• 10 Rao VR, Rolston JD. Unearthing the mechanisms of responsive neurostimulation for epilepsy. Commun Med (Lond) 2023; 3 (01) 166
• 11 Sheybani L. Deep brain stimulation for epilepsy: Dr. Robert Fisher. Epigraph 2022; 24 (01) 14-21
• 12 Walton D, Spencer DC, Nevitt SJ, Michael BD. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database Syst Rev 2021; 4 (04) CD011025
• 13 Cornelssen C, Finlinson E, Rolston JD, Wilcox KS. Ultrasonic therapies for seizures and drug-resistant epilepsy. Front Neurol 2023; 14: 1301956
• 14 Leijten FSS. Dutch TeleEpilepsy Consortium. Multimodal seizure detection: a review. Epilepsia 2018; 59 (Suppl. 01) 42-47
• 15 Li J, Mo D, Hu J. et al. PEDOT:PSS-based bioelectronics for brain monitoring and modulation. Microsyst Nanoeng 2025; 11 (01) 87
• 16 Sheikh SR, McKee ZA, Ghosn S. et al. Machine learning algorithm for predicting seizure control after temporal lobe resection using peri-ictal electroencephalography. Sci Rep 2024; 14 (01) 21771
• 17 Kunekar P, Gupta MK, Gaur P. Detection of epileptic seizure in EEG signals using machine learning and deep learning techniques. J Eng Appl Sci (Asian Res Publ Netw) 2024; 71: 21
• 18 Cook MJ, O'Brien TJ, Berkovic SF. et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol 2013; 12 (06) 563-571

Publication History

Article published online:
13 August 2025